Pulmonology

Investigators found that among adolescents that began as never users, e-cigarette users were more likely to become experimental, infrequent or frequent combustible cigarette users.

Many trials for monoclonal antibody therapies for asthma reported small percentages of African American or Hispanic participants, and some didn’t report racial/ethnic demographics at all.

The biologic AR101 was previously shown to significantly desensitize peanut allergies in a pediatric and adolescent patient population.

The AR101 oral therapy—a biologic designed to desensitize peanut allergies, manufactured by Aimmune Therapeutics—is anticipated to be submitted for FDA approval in the next month.

Study co-author Nicola Alexander Hanania, MD, explains what the new data means for practicing pulmonologists and allergists.

Busse explains the importance of having an additional treatment option and covers best practices for prescribing.

FF/VI met primary and secondary endpoints in increasing the mean proportion of days covered and time to index treatment discontinuation.

On the bright side: In-hospital education shown to be effective in helping bridge the gap.

Sterilizing or hand washing pacifiers doesn’t have the same allergy-suppressing benefits as sucking on them, according to new research.

In a real-world setting, omalizumab improved UAS scores, DLQI scores, response scores, and saw a similar or better safety profile.

The therapy saw similar safety and efficacy profiles across the BORA, SIROCCO and CALIMA studies for the treatment of asthma.

About 21% to 74% of patients with AF will also have obstructive sleep apnea. What is one medical center doing to find these patients in their cardiology department?

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.

The FDA has accepted Sanofi’s supplemental biologics license application (sBLA) for priority review of dupilumab (Dupixent) in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

The most reliable practice for helping a patient quit is comprehensive, and catered to their medical, physical, and financial goals.

Patients with inappropriate medication use lived farther from their preferred pharmacy than those with appropriate use—a median distance difference of just more than 1 mile.

The interleukin pathway-targeting monoclonal antibody has been previously approved for adult atopic dermatitis, and is being considered for a handful more inflammatory or allergic conditions.

Investigators used EHR data to identify epilepsy patients at risk for obstructive sleep apnea and refer them for polysomnography.